Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant Klebsiella pneumoniae

被引:0
作者
Wang, Guangfen [1 ]
Zhang, Hui [2 ]
Wu, Qiaoping [3 ]
Xu, Jianqiang [3 ]
Qiu, Xuedan [3 ]
Chen, Jinyuan [3 ]
Cui, Fujie [3 ]
Zhou, Jian [4 ]
Li, Qingcao [3 ]
机构
[1] Ningbo Univ, Dept Hosp Infect Control, Affiliated Li Huili Hosp, Ningbo, Peoples R China
[2] Ninghai Cty Chengguan Hosp, Dept Clin Lab, Ningbo, Peoples R China
[3] Ningbo Univ, Affiliated Li Huili Hosp, Dept Clin Lab, Ningbo, Peoples R China
[4] Ningbo Univ, Affiliated Li Huili Hosp, Dept Clin Infect Dis, Ningbo, Peoples R China
关键词
CRKP; carbapenemase; ceftazidime-avibactam; aztreonam; combined drug sensitivity; ANTIBIOTIC-RESISTANCE; EPIDEMIOLOGY; MANAGEMENT;
D O I
10.3389/fmicb.2025.1542029
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objective This study aims to investigate the synergistic effects and biofilm inhibition mechanisms of ceftazidime-avibactam (CZA) combined with aztreonam (ATM) against carbapenem-resistant Klebsiella pneumonia (CRKP) commonly found in the local clinical setting, providing new insights for clinical anti-infective strategies. Methods We selected a total of 150 non-duplicate clinical isolates of CRKP from multiple hospitals in Ningbo. Common carbapenemase genes were detected using PCR. Broth microdilution and time-kill assays were used to evaluate the in vitro synergistic effects of CZA and ATM, both individually and in combination, on CRKP isolates with different enzyme types, and the fractional inhibitory concentration index (FICI) was calculated. The crystal violet staining method and bacterial cell permeability assay were employed to assess the impact of CZA, ATM, and their combination on the cell structure and biofilm formation capacity of CRKP. Real-time quantitative PCR (qRT-PCR) was used to measure the expression levels of biofilm-related genes (Luxs, mrkA, wbbM, pgaA, and wzm) in CRKP under treatment with CZA, ATM, or their combination. Results The comparison of synergistic indices for different enzyme-type CRKP strains with CZA and ATM combination therapy showed a statistically significant difference (p < 0.01). The time-kill assay indicated that the time-kill curves for strains carrying blaKPC-2 and blaNDM-1 resistance genes were similar between the monotherapy and combination therapy groups, while the CZA + ATM combination therapy group showed a significant decrease in bacterial concentration after 4-8 h of cultivation compared to the CZA and ATM monotherapy groups. The crystal violet staining and bacterial cell permeability assays demonstrated that the CZA + ATM combination significantly reduced biofilm formation and increased cellular structure disruption in CRKP. The qRT-PCR results showed that CZA combined with ATM notably decreased the expression levels of biofilm-related genes Luxs, mrkA, wbbM, pgaA, and wzm in CRKP. Conclusion The combination of ATM and CZA shows a strong synergistic antibacterial effect against CRKP strains with various enzyme types, with particularly notable synergy in strains carrying the blaKPC-2 resistance gene. Additionally, this combination significantly disrupts the cellular structure of CRKP and inhibits biofilm formation.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
    Guanhao Zheng
    Jianxin Zhang
    Bei Wang
    Jiaqi Cai
    Lili Wang
    Kaixuan Hou
    Yan Zhang
    Liang Zhang
    Zhitao Yang
    Juan He
    Xiaolan Bian
    Infectious Diseases and Therapy, 2021, 10 : 1699 - 1713
  • [32] In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Enterobacterales Isolates from South Korea
    Kim, Taeeun
    Lee, Seung Cheol
    Bae, Moonsuk
    Sung, Heungsup
    Kim, Mi-Na
    Jung, Jiwon
    Kim, Min Jae
    Kim, Sung-Han
    Lee, Sang-Oh
    Choi, Sang-Ho
    Kim, Yang Soo
    Chong, Yong Pil
    ANTIBIOTICS-BASEL, 2020, 9 (12): : 1 - 12
  • [33] Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
    Zheng, Guanhao
    Zhang, Jianxin
    Wang, Bei
    Cai, Jiaqi
    Wang, Lili
    Hou, Kaixuan
    Zhang, Yan
    Zhang, Liang
    Yang, Zhitao
    He, Juan
    Bian, Xiaolan
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (03) : 1699 - 1713
  • [34] Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India
    Sree, Racha Amarthya
    Gupta, Anand
    Gupta, Nitin
    Veturi, Sadhana
    Reddy, L. Siva Kumar
    Begum, Masrath
    Shravani, Etrouth
    Challa, HariPriya Reddy
    Reddy, Satti Santhosh
    Singamsetty, Adarsh
    Arumilli, Murthy
    Reddy, P. Naveen
    Tirlangi, Praveen Kumar
    INFECTION, 2024, 52 (02) : 429 - 437
  • [35] Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam
    Kazmierczak, Krystyna M.
    Biedenbach, Douglas J.
    Hackel, Meredith
    Rabine, Sharon
    de Jonge, Boudewijn L. M.
    Bouchillon, Samuel K.
    Sahm, Daniel F.
    Bradford, Patricia A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) : 4490 - 4500
  • [36] The Rapid Emergence of Ceftazidime-Avibactam Resistance Mediated by KPC Variants in Carbapenem-Resistant Klebsiella pneumoniae in Zhejiang Province, China
    Liu, Congcong
    Wu, Yuchen
    Huang, Ling
    Zhang, Yanyan
    Sun, Qiaoling
    Lu, Jiayue
    Zeng, Yu
    Dong, Ning
    Cai, Chang
    Shen, Zhangqi
    Chen, Gongxiang
    Zhang, Rong
    ANTIBIOTICS-BASEL, 2022, 11 (06):
  • [37] Rational evaluation of the clinical application of ceftazidime-avibactam for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: A real-world retrospective study
    Shi, Jinfang
    Gao, Jie
    Zhu, Ying
    Zhao, Chenyan
    Wang, Wei
    Chen, Shiqi
    Yao, Qingqing
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2025, 111 (03)
  • [38] Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone in China
    Li, Xi
    Quan, Jingjing
    Ke, Huanhuan
    Wu, Wenhao
    Feng, Yu
    Yu, Yunsong
    Jiang, Yan
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [39] The Comparative Efficacy of Ceftazidime-Avibactam with or without Aztreonam vs Polymyxins for Carbapenem-resistant Enterobacteriaceae Infections: A Prospective Observational Cohort Study
    Vijayakumar, M.
    Selvam, Velmurugan
    Renuka, M. K.
    Rajagopalan, Ram Eachambadi
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2023, 27 (12) : 923 - 929
  • [40] Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales
    Satlin, Michael J.
    Chen, Liang
    Gomez-Simmonds, Angela
    Marino, Jamie
    Weston, Gregory
    Bhowmick, Tanaya
    Seo, Susan K.
    Sperber, Steven J.
    Kim, Angela C.
    Eilertson, Brandon
    Derti, Sierra
    Jenkins, Stephen G.
    Levi, Michael H.
    Weinstein, Melvin P.
    Tang, Yi Wei
    Hong, Tao
    Juretschko, Stefan
    Hoffman, Katherine L.
    Walsh, Thomas J.
    Westblade, Lars F.
    Uhlemann, Anne Catrin
    Kreiswirth, Barry N.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (12) : 2066 - 2075